Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose 3F8/GM-CSF + Isotretinoin in High-Risk Neuroblastoma
NCT01183884Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2010
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2010; status: terminated.
02
Drugs
anti-GD2 monoclonal antibody 3F8
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01183884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183884.